Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Myelodysplastic Syndrome Treatment & Management

  • Author: Prasad Mathew, MBBS, DCH, FAAP; Chief Editor: Jennifer Reikes Willert, MD  more...
 
Updated: Dec 10, 2015
 

Approach Considerations

Administer supportive care until the diagnosis is established. Many patients present with profound cytopenia and a notable risk for infection. Transfusions and broad-spectrum antibiotics may be required to treat life-threatening anemia, thrombocytopenia, and infection until definitive therapy can be started.

In patients with refractory cytopenia, hematopoietic stem cell transplantation (HSCT) from a matched related or well-matched unrelated donor early in the course of the disease is the treatment of choice, especially in those with monosomy 7, 7q-, or complex karyotype. Family members of children with monosomy 7 cytogenetics should be evaluated for familial monosomy 7.

Children with refractory cytopenia and a normal karyotype or chromosomal abnormalities other than aberrations of chromosome 7 and absence of transfusion dependency or severe neutropenia may be carefully observed over time. If the cytopenias necessitate treatment, then options include HSCT with either myeloablative or reduced intensity preparative therapies.

Treatment with hematopoietic growth factors may be indicated.

Splenectomy may prove helpful in patients with marked splenomegaly or hypersplenia. The great risk is infection, as is the case with any patient who is asplenic. No significant change in the event-free survival rate is noted in splenectomized patients who undergo hematopoietic stem cell rescue.

Some patients may respond to immunosuppressive therapy with cyclosporine and antithymocyte globulin. Yoshimi et al reported a pilot study involving 29 children who received therapy with these agents.[22] At 6 months, 22 children had a complete or partial response. Six patients were subsequently transplanted for nonresponse, progression, or evolution of monosomy 7. Overall and failure-free survivals were 89% and 55%, respectively.

No dietary restrictions are needed. Patients should take adequate amounts of folate and vitamin B-12. Limitation of iron intake may be necessary in patients who are transfusion dependent. Activity should be undertaken as tolerated. Restriction of activity when platelet counts are low is necessary to prevent hemorrhagic complications from minor trauma.

Consultation may be indicated with a pediatric hematologist/oncologist. A clinical geneticist may provide an invaluable opinion for many children because of the notable association of MSD with other anomalies. Patients should be referred to centers affiliated with major multicenter pediatric oncologic groups.

Children should be monitored often because of the propensity of these disorders to transform to AML. Patients often require frequent transfusions, and their blood cell counts must be monitored at least monthly. Repeated transfusions may result in iron overload, requiring chelation therapy. However, iron overload is observed most often in adults with MDS related to transfusions over a prolonged course.

Patients who have undergone myeloablative therapy with stem cell rescue should be monitored for long-term sequelae, including short stature, obesity, gonadal failure, hypothyroidism, and cataracts.

Next

Hematopoietic Stem Cell Transplantation

Because MDS is a clonal early stem-cell disorder with very limited residual nonclonal stem cells, myeloablative therapy is the only treatment option with a realistic curative potential. Regimens for hematopoietic stem cell rescue result in a 30-50% event-free survival (EFS) rate at 3 years. Outcomes improve in children who are relatively young and who receive hematopoietic stem cell rescue soon after diagnosis.

Myeloablative therapy with hematopoietic stem cell rescue from a human leukocyte antigen (HLA)–matched sibling is the best therapy for MDS. For children who do not have an eligible sibling donor, alternative donors should be sought, although outcome is even less favorable than it is with a sibling donor. A study by Lang et al reported 5-year EFS rates of 60% and 47% for HSCT using matched sibling donors or compatible unrelated donors, respectively.[23]

In a cohort of 27 children with refractory cytopenia, Yusuf et al reported an estimated survival probability of 0.74 following various high-intensity conditioning regimens.[24] In an Italian study involving 49 children, using the busulfan/cyclophosphamide regimen, the 5-year estimate of EFS rate was 77%, whereas the 5-year cumulative incidence of transplantation-related mortality and disease recurrence were 19% and 2%, respectively.

A cohort of 16 children, 14 of whom met the criteria for MDS, received allogeneic stem cell transplants. Median age was 4.8 years (range 1-14 y). The median time from diagnosis to transplant was 6 months. Eleven of 14 patients were conditioned with a busulphan-based myeloablative regimen, with the addition of low-dose etoposide, and all but one received a bone marrow graft. Nine patients achieved complete remission. At a median follow-up of 3 years (range 2-14 y), the overall survival and EFS was 57% (95% confidence interval, 0.28-0.78). Cumulative EFS at 10 y was 43% (95% confidence interval, 0.14-0.70). Relapse-related mortality was 21.4%.[25]

In a single-center experience with 37 consecutive pediatric MDS patients (20 had primary MDS, and 17 had secondary MDS) who received myeloablative HSCT (majority received cyclophosphamide/total body irradiation conditioning regimen),the overall survival and disease-free survival at 10 years was 53% and 45%, respectively. Monosomy 7 was present in 21, trisomy 8 in 7, and normal cytogenetics in 8. According to the modified WHO criteria, 30 had RC and 7 had RAEB. The 3-year disease-free survival in patients who did not receive pre-HSCT chemotherapy and those who had a shorter interval to transplantation (< 140 d) was 80%.[26]

These data indicate that transplant-related mortality represents the main cause of treatment failure. Using a reduced-intensity conditioning regimen with fludarabine, Strahm et al reported that in 19 children with refractory cytopenia, the 3-year overall survival and EFS were 0.84 and 0.74, respectively.[27]

In patients with myelodysplastic syndrome (MDS) who have an increased blast count, allogeneic HSCT is the treatment of choice. Toxicity of the procedure and relapse rate contribute equally to the number of adverse events.

Whether intensive chemotherapy should be routinely administered prior to HSCT is highly controversial. In the United States and United Kingdom, children with refractory anemia with excess blasts (RAEB) and RAEB in transition to acute myeloid leukemia (AML) are generally included in pediatric AML trials.

Most AML studies have reported significant morbidity and mortality in patients with MDS, and an overall survival of less than 30%.[28, 29] Zecca et al reported that AML-type therapy prior to HSCT did not prolong survival in 101 children with MDS and an increased blast count.

Previous
Next

Agents Used in Adults

The US Food and Drug Administration (FDA) has approved 3 agents for treatment of adult MDS since 2004: azacitidine (Vidaza), decitabine (Dacogen) and lenalidomide (Revlimid). None of these compounds have been approved for the pediatric population. Studies should be undertaken to elucidate the efficacy of these agents in the pediatric population.

In adults, lenalidomide is approved for the treatment of transfusion-dependent anemia in patients with MDS and chromosome 5q deletion. In the pivotal trial, 76% of patients had a 50% or greater reduction in transfusions, with 67% achieving transfusion independence.[30] Achievement of transfusion independence strictly correlated with cytogenetic response. In addition, cytogenetic response had the highest predictive value for prolonged survival in a multivariate analysis, as well as a statistically significant decreased risk for AML progression.

Azacitidine and decitabine have become established as part of the standard medications in the treatment of MDS in adults. In a phase III study of azacitidine, Silverman et al reported an overall response rate of 60% in 191 patients, with 7% complete response, 16% partial response, and 37% hematological response.[31] In a phase III study using decitabine, Kantarian et al reported an overall response rate of 17% in 170 patients, with 9% complete response, 8% partial response, and 13% hematologic response.[32]

Data from a study by Bernal et al showed that despite widespread use of azacitidine, there is a lack of improvement in long-term survival of patients with high-risk myelodysplastic syndromes.[33, 34]

Previous
Next

Growth Factor Therapy

The use of erythropoietin is helpful in patients who have low erythropoietin levels. Recent data from a phase III adult trial by the Eastern Cooperative group (ECOG) showed that erythropoietin treatment improved overall survival in patients responding to the erythropoiesis-stimulating agents compared with the best supportive care management.[35] This has also been confirmed by the Nordic and French MDS Study Groups.

Granulocyte colony-stimulating factor (G-CSF) has also been used, with a transient improvement in neutropenia.

Hesitation in using growth factors has been based on the known increased response of myelodysplastic clones to granulocyte-macrophage colony-stimulating factor (GM-CSF) and on reports that the use of G-CSF in children with severe aplastic anemia is associated with the later development of MDS or AML.

Previous
 
 
Contributor Information and Disclosures
Author

Prasad Mathew, MBBS, DCH, FAAP Professor of Pediatrics, Division of Hematology/Oncology, University of New Mexico School of Medicine

Prasad Mathew, MBBS, DCH, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society on Thrombosis and Haemostasis, American Society of Clinical Oncology, National Hemophilia Foundation, Hemophilia and Thrombosis Research Society, International Society of Paediatric Oncology, World Federation of Hemophilia

Disclosure: Received salary from Bayer HC for payment for services rendered.

Coauthor(s)

Glenda H Grawe, MD Assistant Professor of Pediatrics, Baylor College of Medicine; Attending Physician, Department of Pediatrics, Section of Emergency Medicine, Texas Children's Hospital

Glenda H Grawe, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Emergency Physicians, Minnesota Medical Association, National Association of EMS Physicians, Texas Pediatric Society, Harris County Medical Society

Disclosure: Received honoraria from Draeger for review panel membership.

Franklin O Smith, III, MD Clinical Director, University of Cincinnati Cancer Institute, Professor of Medicine, Associate Director, Hematology/Oncology Fellowship Training Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine; Professor of Pediatrics With Tenure, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine

Franklin O Smith, III, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Pediatric Society, American Society of Gene and Cell Therapy, American Society of Hematology, American Society of Pediatric Hematology/Oncology, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, International Society of Paediatric Oncology

Disclosure: Received consulting fee from Wyeth Research for consulting; Received from Seattle Genetics for other.

Chief Editor

Jennifer Reikes Willert, MD Associate Clinical Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Section of Stem Cell Transplantation, Stanford University Medical Center, Lucile Packard Children's Hospital

Jennifer Reikes Willert, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society for Blood and Marrow Transplantation, Children's Oncology Group, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Acknowledgements

Timothy P Cripe, MD, PhD Professor of Pediatrics, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center; Clinical Director, Musculoskeletal Tumor Program, Co-Medical Director, Office for Clinical and Translational Research, Cincinnati Children's Hospital Medical Center; Director of Pilot and Collaborative Clinical and Translational Studies Core, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine

Timothy P Cripe, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Kathleen M Sakamoto, MD, PhD Professor and Chief, Division of Hematology-Oncology, Vice-Chair of Research, Mattel Children's Hospital at UCLA; Co-Associate Program Director of the Signal Transduction Program Area, Jonsson Comprehensive Cancer Center, California Nanosystems Institute and Molecular Biology Institute, University of California, Los Angeles, David Geffen School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society for Experimental Hematology, Society for Pediatric Research, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994 Aug. 87(4):746-54. [Medline].

  2. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003 Feb. 17(2):277-82. [Medline].

  3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005 Apr 1. 103(7):1457-67. [Medline].

  4. Velloso ED, Chauffaille ML, Pelicario LM, et al. Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases: challenges and difficulties in a large and emerging country. Braz J Med Biol Res. 2013 Jan. 46(1):85-90. [Medline].

  5. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000 Sep. 110(4):768-79. [Medline].

  6. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998 Jan 15. 91(2):608-15. [Medline].

  7. Smith OP. Shwachman-Diamond syndrome. Semin Hematol. 2002 Apr. 39(2):95-102. [Medline].

  8. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994 Sep 1. 84(5):1650-5. [Medline].

  9. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. 2000 Jul 15. 96(2):429-36. [Medline].

  10. Willig TN, Niemeyer CM, Leblanc T, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. Pediatr Res. 1999 Nov. 46(5):553-61. [Medline].

  11. Ohara A, Kojima S, Okamura J, et al. Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol. 2002 Jan. 116(1):151-4. [Medline].

  12. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997 Aug 1. 90(3):1009-13. [Medline].

  13. Kim M, Kook H, Park HJ, Ahn HS, Lee KC, Lee KS. Quantitative Comparison of CDKN2B Methylation in Pediatric and Adult Myelodysplastic Syndromes. Acta Haematol. 2013. 130:115-21. [Medline].

  14. Blank J, Lange B. Preleukemia in children. J Pediatr. 1981 Apr. 98(4):565-8. [Medline].

  15. Greenberg PL, Mara B. The preleukemic syndrome: correlation of in vitro parameters of granulopoiesis with clinical features. Am J Med. 1979 Jun. 66(6):951-8. [Medline].

  16. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia. 1995 Sep. 9(9):1569-72. [Medline].

  17. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999 Jan 15. 93(2):459-66. [Medline].

  18. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006 Dec. 91(12):1588-90. [Medline].

  19. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30. 364(26):2496-506. [Medline]. [Full Text].

  20. Bresolin S, Trentin L, Zecca M, Giordan M, Sainati L, Locatelli F. Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia. 2012 Jul. 26(7):1717-9. [Medline].

  21. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia. 1999 Mar. 13(3):376-85. [Medline].

  22. Yoshimi A, Baumann I, Führer M, et al. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica. 2007 Mar. 92(3):397-400. [Medline].

  23. Lang P, Greil J, Bader P, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004 Nov-Dec. 33(3):281-7. [Medline].

  24. Yusuf U, Frangoul HA, Gooley TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant. 2004 Apr. 33(8):805-14. [Medline].

  25. Al-Seraihy A, Ayas M, Al-Nounou R, El-Solh H, Al-Ahmari A, Al-Jefri A. Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. Hematol Oncol Stem Cell Ther. 2011. 4(3):121-5. [Medline].

  26. Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE. Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. Pediatr Blood Cancer. 2013 Apr. 60(4):705-10. [Medline].

  27. Strahm B, Locatelli F, Bader P, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant. 2007 Aug. 40(4):329-33. [Medline].

  28. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug. 87(4):743-5. [Medline].

  29. Hasle H, Kerndrup G, Yssing M, et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia. 1996 Aug. 10(8):1269-73. [Medline].

  30. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5. 355(14):1456-65. [Medline].

  31. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15. 20(10):2429-40. [Medline].

  32. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15. 106(8):1794-803. [Medline].

  33. Bernal T, Martínez-Camblor P, Sánchez-García J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015 Sep. 29 (9):1875-81. [Medline].

  34. Raymond J. Azacitidine May Not Improve Long-Term Survival In Myelodysplastic Syndromes. Reuters Health Information. Available at http://www.medscape.com/viewarticle/844723. May 15, 2015; Accessed: December 11, 2015.

  35. Miller K, Haesook K, Greenberg P, et al. Phase III prospective randomized trial of EPO with or without G-CSF versus supportive care in the treatment of MDS: results of the ECOG-CLSG trial. Blood. 2004. 104:70.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.